James S Rush
Overview
Explore the profile of James S Rush including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Alper P, Deane J, Betschart C, Buffet D, Collignon Zipfel G, Gordon P, et al.
Bioorg Med Chem Lett
. 2020 Aug;
30(17):127366.
PMID: 32738975
Antagonism of the Toll-like receptors (TLRs) 7 and TLR8 has been hypothesized to be beneficial to patients suffering from autoimmune conditions. A phenotypic screen for small molecule antagonists of TLR7/8...
12.
Espie P, He Y, Koo P, Sickert D, Dupuy C, Chokote E, et al.
Am J Transplant
. 2019 Oct;
20(2):463-473.
PMID: 31647605
Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics,...
13.
Kahaly G, Stan M, Frommer L, Gergely P, Colin L, Amer A, et al.
J Clin Endocrinol Metab
. 2019 Sep;
105(3).
PMID: 31512728
Context: The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Objective: Evaluate efficacy and safety of a human, blocking,...
14.
Wieczorek G, Bigaud M, Pfister S, Ceci M, McMichael K, Afatsawo C, et al.
Ann Rheum Dis
. 2019 Mar;
78(7):974-978.
PMID: 30902822
Objective: To examine the role of CD40-CD154 costimulation and effects of therapeutic pathway blockade in the non-obese diabetic (NOD/ShiLtJ) model of Sjögren's syndrome (SS). Methods: We assessed leucocyte infiltration in...
15.
Ulrich P, Flandre T, Espie P, Sickert D, Rubic-Schneider T, Shaw D, et al.
Toxicol Sci
. 2018 Aug;
166(1):192-202.
PMID: 30099540
CFZ533 is a pathway blocking, nondepleting anti-CD40 antibody that is in clinical development for inhibition of transplant organ rejection and therapy for autoimmune diseases. A 26-week GLP toxicity study in...
16.
Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, et al.
Am J Transplant
. 2018 Apr;
18(12):2895-2904.
PMID: 29665205
The CD40-CD154 costimulatory pathway is essential for T cell-dependent immune responses, development of humoral memory, and antigen presenting cell function. These immune functions have been implicated in the pathology of...
17.
Santone M, Aprea S, Wu T, Cooke M, Mbow M, Valiante N, et al.
Hum Vaccin Immunother
. 2015 May;
11(8):2038-50.
PMID: 26024409
Cross-presentation is the process by which professional APCs load peptides from an extracellularly derived protein onto class I MHC molecules to trigger a CD8(+) T cell response. The ability to...
18.
Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, et al.
J Immunol
. 2015 Mar;
194(8):3723-34.
PMID: 25762782
The paracaspase MALT1 plays an important role in immune receptor-driven signaling pathways leading to NF-κB activation. MALT1 promotes signaling by acting as a scaffold, recruiting downstream signaling proteins, as well...
19.
Rush J, Liu M, Odegard V, Unniraman S, Schatz D
Proc Natl Acad Sci U S A
. 2005 Sep;
102(37):13242-7.
PMID: 16141332
Class switch recombination (CSR) is the process by which B cells alter the effector function properties of their Ig molecules. The decision to switch to a particular Ig isotype is...
20.
Rush J, Fugmann S, Schatz D
Int Immunol
. 2004 Mar;
16(4):549-57.
PMID: 15039385
Class switch recombination (CSR) is the process whereby B cells alter the effector properties of their Ig molecules. Whilst much is known about the cellular regulation of this process, many...